GeronFRA:GON -0.52%39 Quick Ratio is 4.96 as of Mar. 2026, which is 28% below its 10-year median of 6.88. GuruFocus rates FRA:GON with a GF Score™ of 39/100 and a GF Value™ of €5.57 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,412 Biotechnology companies, Geron ranks better than 59.7% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Geron's quick ratio for the quarter that ended in Mar. 2026 was 4.96.
Geron has a quick ratio of 4.96. It generally indicates good short-term financial strength.
The historical rank and industry rank for Geron's Quick Ratio or its related term are showing as below:
FRA:GON'
s Quick Ratio Range Over the Past 10 Years
Min: 2.35 Med: 6.88 Max: 37.8
Current: 4.96
During the past 13 years, Geron's highest Quick Ratio was 37.80. The lowest was 2.35. And the median was 6.88.
FRA:GON's Quick Ratio is ranked better than 59.7% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:GON: 4.96
Geron (FRA:GON) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Geron Quick Ratio Related Terms
Geron Quick Ratio Historical Data
* Premium members only.
The historical data trend for Geron's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GON vs SPRY, PHAT, DSGN: Quick Ratio Comparison
For the Biotechnology subindustry, Geron's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geron Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geron's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Geron's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Geron's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geron (FRA:GON) has a Quick Ratio of 4.96 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Geron and its competitors. This is 28% below median its historical median of 6.88. Over the past decade, Geron's Quick Ratio has ranged from 2.35 to 37.80. According to the industry distribution chart, Geron ranks #569 out of 1412 companies in the Biotechnology industry, placing it in the top 40.3%.
Is Geron's Quick Ratio too high?
Geron's current Quick Ratio of 4.96 is 28% below median its 10-year median of 6.88. Over the past 10 years, this metric has ranged from a low of 2.35 to a high of 37.80. The Biotechnology industry median Quick Ratio is 3.60. Geron's value of 4.96 is 37.8% above this industry median. Based on the distribution chart, Geron ranks #569 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Geron has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's Quick Ratio compare to SPRY and PHAT?
According to the Biotechnology industry distribution chart, Geron ranks #569 out of 1412 companies for Quick Ratio. This puts Geron in the upper half of its industry. The industry median Quick Ratio is 3.60. Geron's value of 4.96 is 37.8% above this benchmark. Historically, Geron's own Quick Ratio has ranged from 2.35 to 37.80 over the past decade. While the company's 10-year median is 6.88 vs. the industry median of 3.60, Geron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Geron's current Quick Ratio of 4.96 is 37.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Geron and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geron's current Quick Ratio is 4.96, which is 28% below median its own 10-year median of 6.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (FRA:GON) is currently considered Possible Value Trap. The stock's GF Value™ is €5.57, compared to a current price of €1.14 — trading 79.5% below its estimated fair value. The current Quick Ratio is 4.96, which is 28% below median its 10-year median of 6.88 and 37.8% above the Biotechnology industry median of 3.60. Geron's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Geron (FRA:GON), the current Quick Ratio is 4.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geron (FRA:GON) Overvalued in 2026?
Based on GuruFocus' analysis, Geron stock appears to be undervalued.
The current stock price of €1.14 is trading 79.5% below its estimated GF Value™ of €5.57.
GuruFocus considers Geron to be Possible Value Trap.
Key valuation signals for FRA:GON:
Quick Ratio: 4.96 (28% below median its 10-year median of 6.88)
GF Value™: €5.57 vs. price of €1.14 (79.5% below fair value)
Industry Position: 37.8% above the Biotechnology median (#569 of 1412)
No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
39GF Score
Get the complete analysis for FRA:GON
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GON has been successfully added to your 
